FineTest ELISA kit contributes to the research on luminal breast cancer. The immunoassay is designed to measure SCUBE2 concentration in serum samples.
Article Title: SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches
Journal Title: Cell Research
Abstract: Estrogen receptor (ER)-positive luminal breast cancer is a subtype with generally lower risk of metastasis to most distant organs. The mechanisms of this subtype-specific organotropism remain elusive. Here we show that an ER-regulated secretory protein SCUBE2 contributes to bone tropism of luminal breast tumor. Single-cell RNA sequencing analysis reveals osteoblastic enrichment by SCUBE2 in early bone-metastatic niches. SCUBE2 facilitates release of tumor membrane-anchored SHH to activate Hedgehog signaling in mesenchymal stem cells, thus promoting osteoblast differentiation. Osteoblasts deposit collagens to suppress NK cells via the inhibitory LAIR1 signaling and promote tumor colonization. SCUBE2 expression and secretion are associated with osteoblast differentiation and bone metastasis in human tumors. Targeting Hedgehog signaling with Sonidegib and targeting SCUBE2 with a neutralizing antibody both effectively suppress bone metastasis in multiple metastasis models. Overall, our findings provide a mechanistic explanation for bone preference in luminal breast cancer metastasis and new approaches for metastasis treatment.
Keywords: Breast Cancer, Bone metastases, Cancer microenvironment
|FineTest Product||Sample||Detection Target|
|Human SCUBE2(Signal peptide, CUB and EGF-like domain-containing protein 2) ELISA Kit(EH4343)||serum||SCUBE2|
|Mouse SHH(Hedgehog Homolog, Sonic) ELISA Kit(EM1360)||SHH|
Figure Source: Cell Res. 2023 May 4. doi: 10.1038/s41422-023-00810-6.